NEFF DEBORAH J 4

What Happened

• Deborah J. Neff, a director of Cytek Biosciences (CTKB), had derivative units converted/exercised into 43,973 shares on June 10, 2026 and was also granted RSU awards totaling 51,594 shares (33,333 + 18,261). The filing shows the 43,973 shares were acquired via exercise/conversion and the same 43,973 shares were simultaneously disposed at $0.00. All reported transactions show $0.00 purchase/sale prices or N/A for value in the filing.

Key Details

• Transaction date: June 10, 2026 (Form 4 filed June 12, 2026).
• Derivative conversion/exercise: 43,973 shares acquired (code M); 43,973 shares disposed at $0.00 (code M) on same date.
• RSU awards: 33,333 and 18,261 RSUs granted (code A) at $0.00 (derivative awards), totaling 51,594 RSUs.
• Vesting/conversion notes from filing:
  • Each RSU represents a contingent right to one share (F1).
  • Footnote F4 states 100% of the RSU Award vested on June 10, 2026.
  • Footnotes F2/F3 describe typical vesting schedules for other awards/options (vesting by June 10, 2027 or the 2027 annual meeting).
• Shares owned after the transactions: not specified in the provided excerpt.
• Filing timing: Form 4 was filed two days after the transactions (June 12), within the normal two-business-day filing window.

Context

• The filing records both an acquisition (conversion/exercise) and an immediate disposition of the same 43,973 shares at $0.00. Such same-day acquisition-and-disposition entries commonly reflect conversion of restricted stock/RSUs into shares followed by surrender or transfer of shares (for example, to satisfy tax-withholding obligations), but the filing itself shows the disposition amount as $0.00 and provides the vesting footnote (F4) confirming the RSUs vested on June 10, 2026.
• These events are awards/vesting and internal conversions rather than open-market purchases or profitable sales; they do not by themselves indicate a directional buy/sell opinion by the insider.